Background-Novel oral anticoagulants (NOACs) have been shown to be at least as good as warfarin for preventing stroke or transient ischemic attack in patients with atrial fibrillation, yet diffusion of these therapies and patterns of use among atrial fibrillation patients with ischemic stroke and transient ischemic attack have not been well characterized. Methods and Results-Using data from Get With The Guidelines-Stroke, we identified a cohort of 61 655 atrial fibrillation patients with ischemic stroke or transient ischemic attack hospitalized between October 2010 and September 2012 and discharged on warfarin or NOAC (either dabigatran or rivaroxaban). Multivariable logistic regression was used to identify factors associated with NOAC versus warfarin therapy. In our study population, warfarin was prescribed to 88.9%, dabigatran to 9.6%, and rivaroxaban to 1.5%. NOAC use increased from 0.04% to a 16% to 17% plateau during the study period, although anticoagulation rates among eligible patients did not change appreciably (93.7% versus 94.1% from first quarter 2011 to second quarter 2012), suggesting a trend of switching from warfarin to NOACs rather than increased rates of anticoagulation among eligible patients. Several bleeding risk factors and CHA 2 DS 2 -VASc scores were lower among those discharged on NOAC versus warfarin therapy (47.9% versus 40.9% with CHA 2 DS 2 -VASc ≤5, P<0.001 for difference in CHA 2 DS 2 -VASc). Conclusions-NOACs have had modest but growing uptake over time among atrial fibrillation patients hospitalized with stroke or transient ischemic attack and are prescribed to patients with lower stroke risk compared with warfarin.
A trial fibrillation (AF) affects >2.5 million people in the United States, and the attributable risk for thromboembolic events ranges from 1.5% to 23.5% depending on the age of individual. 1 Anticoagulation with warfarin reduces this risk by ≈66%. For decades, warfarin was the only oral anticoagulant available for thromboembolic prophylaxis. 2 Nevertheless, warfarin therapy is cumbersome for patients and medical providers because of numerous food and drug interactions, a narrow therapeutic index, and a need for frequent monitoring.
Recently, novel oral anticoagulants (NOACs) have become available for the prevention of thromboembolic events, specifically, the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban and apixaban. Clinical trials show that these agents are at least noninferior to warfarin with regard to thromboembolic prophylaxis for AF and potentially safer on the risk of intracranial hemorrhage. [3] [4] [5] At the same time, these NOACs carry practical advantages, including a decreased need for routine monitoring, a more predictable anticoagulant effect, and cost effectiveness in high-stroke risk populations. 6, 7 Yet provider inexperience and a lack of clear antidote for patients with bleeding complications on NOACs may have initially tempered enthusiasm for these drugs, although clinical trials have demonstrated similar risks of major bleeding and significant reductions in intracranial hemorrhage compared with warfarin therapy. [3] [4] [5] Little is known about the real-world uptake of these new anticoagulants, particularly in patients with ischemic stroke and transient ischemic attack (TIA).
To address this knowledge gap, we used data from Get With The Guidelines-Stroke (GWTG-Stroke), a national quality improvement initiative and registry with >1800 participating hospitals, to characterize the prevalence, patterns, and predictors of NOAC versus warfarin therapy at discharge among AF patients hospitalized with ischemic stroke or TIA.
Methods

GWTG-Stroke
GWTG-Stroke is a national quality improvement initiative aimed at improving stroke care. Details of the GWTG-Stroke program design have been previously published. 8 Hospitals that participate must receive approval through their local institutional review boards or a waiver of individual consent under the common rule. Trained personnel regularly review hospital records to identify patients admitted to participating centers with stroke or TIA. Medical history and demographic data from patient records are abstracted, and deidentified data are entered into a central database using a web-based patient management tool. Quintiles (Cambridge, MA) is the data collection coordination center for the American Heart Association/American Stroke Association GWTG programs. The Duke Clinical Research Institute (Durham, NC) serves as the data analysis center and has an agreement to analyze the aggregate, deidentified data for research purposes. The data are monitored and audited for quality and integrity. 9
Study Population
Using GWTG-Stroke, we analyzed patients with AF who were hospitalized for ischemic stroke or TIA and discharged on warfarin or NOAC between October 19, 2010 and September 27, 2012 . This time period spanned the 2-year time interval after the Food and Drug Administration's approval of dabigatran (the first NOAC on the market for AF stroke prophylaxis), as well as the initial 15 months after the Food and Drug Administration's approval of rivaroxaban. As a result, for the purposes of this study, NOAC refers to dabigatran and rivaroxaban only because apixaban had not yet been approved for general use during the study period. We excluded sites with >25% missing information in the medical history panel, patients with hemorrhagic stroke, or other documented contraindications to anticoagulant therapy, and patients who had no documented discharge destination or transferred out of the initial hospital. Of the 128 740 patients hospitalized with ischemic stroke/TIA and AF during the study period, 22 236 were excluded because of transferring out from the original facility or not having a documented discharge destination, 30 857 were excluded because of a documented contraindication to anticoagulant therapy, 4771 were excluded because of lack of being discharged on any anticoagulant, 7214 were excluded for anticoagulant choice other than NOAC or warfarin, and 2007 were excluded because of conflicting or missing information. The final study population was comprised of 61 655 patients.
Statistical Analysis
Contingency tables were generated to identify important covariables, including demographics, clinical data, medical history, and hospital characteristics. Descriptive data are reported as percentages or as medians with interquartile ranges (IQRs). Pearson χ 2 and Wilcoxon signed-rank tests were used to assess univariate differences among patients discharged on NOACs versus warfarin. Hospital and patient factors associated with discharge NOAC therapy were identified using a multivariable logistic regression model and reported as odds ratios with 95% confidence intervals. The following variables were included in the initial model: age, sex, race, insurance status, stroke diagnosis (TIA versus ischemic stroke), creatinine, systolic blood pressure, preadmission anticoagulant use, heart failure, hypertension, diabetes mellitus, previous stroke/TIA, use of preadmission anticoagulants, prosthetic heart valve, coronary disease/previous myocardial infarction, carotid stenosis, peripheral vascular disease, smoker, dyslipidemia, ambulatory status at discharge, aspirin or clopidogrel at discharge, discharge to home, hospital size, type, and region, and annual intravenous tissue plasminogen activator and stroke volumes. Patients missing information about creatinine, systolic blood pressure, ambulatory status, use of preadmission anticoagulants, and site characteristics were excluded from the regression model for the main analysis (n=14 856 total exclusions). For patients included in logistic regression analysis, missing rates for remaining variables were <5%, with the exception of insurance status with a rate of 11.4%. Missing insurance status was imputed based on age as follows: if age ≥65 then, insurance imputed to Medicare; if age <65 and insurance present, then insurance imputed to other; if insurance was not documented, then insurance status was imputed to self-pay/no insurance. Missing values for medical history were imputed to no, and missing race was imputed to white. Backward selection was used to eliminate highly insignificant factors (P value>0.1), and generalized estimating equations were used to account for within-hospital clustering. Generalized estimating equation methods posit a working correlation structure. For this study, we used exchangeable or compound symmetrical working correlation and empirical SE (ie, sandwich variance). In addition, we performed a sensitivity analysis including patients with missing data for anticoagulant before admission, serum creatinine, systolic blood pressure, and ambulatory status using multiple imputation to handle missing data (total n=61 408 after excluding patients from sites with high missing rates). For categorical variables with k categories, we used a Wald test with k-1 degrees of freedom and reported P value for overall relationship across levels. Temporal changes of discharge anticoagulant use were assessed by calendar quarter using Cochran-Mantel-Haenszel statistics. To assess anticoagulation rates among eligible patients, patients discharged on no anticoagulant (n=4771) or a non-NOAC/nonwarfarin agent (n=7214; including low-molecular weight heparin, unfractionated heparin, fondaparinux, intravenous direct thrombin inhibitors, or other anticoagulants) were also included in the temporal analysis. Additional descriptive data were generated, including CHADS 2 (1 point each for C=congestive heart failure, H=hypertension, A=age ≥75, D=diabetes mellitus, 2 points for S 2 =previous stroke/TIA) and CHA 2 DS 2 -VASc (as with CHADS 2 with exception of A 2 =2 points for age ≥75, V=1 point for vascular disease, A=1 point for age 65-74,
WHAT IS KNOWN
• Novel oral anticoagulants (NOACs) have been shown to be at least as efficacious as warfarin for preventing stroke or transient ischemic attack in patients with nonvalvular atrial fibrillation, yet diffusion of these therapies and patterns of use among hospitalized high-risk atrial fibrillation patients with confirmed ischemic stroke and transient ischemic attack have not been well characterized.
WHAT THE STUDY ADDS
• This study, which is the largest to study NOAC use among 61 655 patients with confirmed ischemic stroke/transient ischemic attack, shows modest NOAC uptake during the study period with overall use of 11.1%. • Despite ease of use of NOACs compared with warfarin, anticoagulation rates among eligible patients did not change appreciably during the first 2 years of NOAC availability, suggesting a trend of switching from warfarin to NOAC therapy. • Using multivariable logistic regression, we identified several variables independently associated with NOAC versus warfarin therapy, including novel factors, such as ambulatory status and discharge destination.
Sc=1 point for female sex) distribution among patients discharged on NOAC versus warfarin, and site-based use of NOAC and warfarin at hospital discharge. For descriptive data, missing rates for all variables were ≤3% with the exception of missing rates of >10% for admission medications, insurance status, and admission ambulatory status, as well as missing rates of >20% for admission laboratory and physical examination values, National Institute of Health stroke scale, and ambulatory status at discharge. All statistical analyses were performed using SAS version 9.1 software (SAS Institute, Cary, NC).
Results
Overall Use
We identified a study population of 61 655 patients from 1542 hospitals with AF/atrial flutter who were admitted with ischemic stroke or TIA and discharged on warfarin or NOAC during our study period; 79.1% of the population has ischemic stroke, and the remainder (20.9%) experienced TIA. AF or atrial flutter was newly diagnosed in 33% of the study population, and this proportion did not differ among those discharged on NOAC or warfarin. Among those discharged on NOAC or warfarin, dabigatran was prescribed to 9.6% (n=5925), rivaroxaban to 1.5% (n=904), and warfarin to 88.9% (n=54 820).
Patient Characteristics (Tables 1 and 2)
For patients discharged on NOAC versus warfarin, 51.8% versus 53.3% (P=0.016) were women and the median age was 77 (IQR, 69-84) versus 79 (IQR, 70-85, P<0.001). The majority of patients discharged on NOAC or warfarin were white (82.7% versus 80.8%, respectively; P=0.001), and slightly higher proportions of patients discharged on NOAC versus warfarin had private/health maintenance organization insurance (41.7% versus 37.6%) than Medicare (39.0% versus 42.3%), Medicaid (5.4% versus 6.3%), or self-pay (1.4% versus 2.2%; P<0.001 for insurance status). Considerably, fewer patients were receiving anticoagulation at hospital admission among those discharged on NOAC versus warfarin (33.1% versus 46.6%; P<0.001). Among patients with nonmissing information about anticoagulant use at admission and NOAC or warfarin use at discharge, use of NOAC versus warfarin was 8.1% versus 91.9% (n=2263 versus 25 562) for those on anticoagulation before hospitalization and 13.9% versus 86.1% (n=3684 versus 22 908) for those not on anticoagulation before hospitalization.
In univariate analyses, rates of diabetes mellitus (26.7% versus 30.0%; P<0.001), previous stroke/TIA (33.6% versus 34.9%; P=0.041), and heart failure (12.8% versus 17.3%, P<0.001)-all well-established risk factors for AF thromboembolism-were significantly lower among those discharged on NOAC versus warfarin. Moreover, patients discharged on NOAC had lower CHADS 2 and CHA 2 DS 2 -VASc scores than those discharged on warfarin therapy (P<0.001; Figure 1 ), with 38.0% versus 31.3% of patients having a CHADS 2 score of ≤3 and 47.9% versus 40.9% with CHA 2 DS 2 -VASc ≤5.
Patients discharged on NOAC versus warfarin had less severe ischemic stroke (median National Institute of Health stroke scale, 3 [IQR, 1-8] versus 5 [IQR, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] ; P<0.001), shorter length of stay (3 [IQR, 2-5] versus 4 [IQR, 2-6] days; P<0.001), and higher proportions of patients who could ambulate at admission (32.5% versus 26.1%; P<0.001) and discharge (47.5% versus 39.2%; P<0.001). More patients discharged on NOAC were discharged to home (65.0%) than a healthcare facility, compared with 52.4% of patients prescribed warfarin being discharged to home (P<0.001). Table 3 shows the results of a multivariable logistic regression model for prescription of NOAC versus warfarin therapy at hospital discharge. Anticoagulation before admission was associated with lower odds for NOAC versus warfarin therapy at discharge (odds ratio, 0.52; 95% confidence interval, 0.48-0.56; P<0.001). Consistent with the prevalent use of dabigatran among NOACs during the study period and safety recommendations, worsening creatinine and prosthetic heart valves were strongly associated with less NOAC therapy. Impaired ambulation, increasing age, discharge antiplatelet therapy, and Medicare or Medicaid insurance status were also associated with reduced NOAC use. Medical history of coronary disease had no association with NOAC therapy despite controversy about increased myocardial infarction risk with dabigatran therapy. A sensitivity analysis using multiple imputation for missing variables did not show appreciably different results but did, in addition, identify female sex, heart failure, and ischemic stroke (versus other type of stroke) to be associated with reduced NOAC use ( Table I in the Data Supplement) , which is consistent with the observation that higher stroke risk is associated with lower NOAC use. Although hospitals in the south had higher odds of NOAC prescription, there was no association with hospital type (academic versus not), bed number, or urban/ rural location on NOAC therapy; however, considerable site-level variation in discharge NOAC use was observed. Of 1347 sites with >5 NOAC prescriptions during the study period, the median rate of discharge NOAC versus warfarin therapy was 9.6% (IQR, 4.0-16.7), with a range from 0% to 62.5% (Figure 2 ).
Predictors of NOAC Therapy
Temporal Variability
We did observe increased NOAC use over time (P for nonzero correlation<0.001; Figure 3 ). Dabigatran was Food and Drug Administration approved for AF stroke prophylaxis in the fourth quarter of 2010, yet NOAC use was nearly absent until the third quarter of 2011 when it increased to 6.4% among patients eligible for anticoagulation. This was the same quarter in which rivaroxaban was approved by the Food and Drug Administration for AF stroke prophylaxis and the quarter after the updated American College of Cardiology/ American Heart Association/Heart Rhythm Society update on the management of patients with AF using dabigatran. 10 There was subsequent rapid uptake with overall NOAC use leveling off in the 16% to 17% range for the remainder of the study period. Warfarin use and non-NOAC/nonwarfarin anticoagulant use declined from the first quarter of 2011 to the second quarter of 2012 (78.8% to 72.4% for warfarin and 14.6% to 4.7% for non-NOAC/nonwarfarin agents). Over these same quarters, the proportion of eligible patients who were not anticoagulated at hospital discharge did not change appreciably (from 6.3%-5.9%).
Discussion
In this study, we examined the diffusion of NOACs in a highstroke risk population using the largest available registry of patients with ischemic stroke and TIA. Although other studies have also demonstrated a modest uptake in NOAC use, this is the largest study to evaluate the use of NOACs in a high-risk population with confirmed stroke or TIA. [11] [12] [13] [14] We also observed considerable variations in NOAC use among hospitals and important differences in risk for recurrent stroke/ TIA and several bleeding risk factors among patients receiving discharge NOAC versus warfarin therapy. Moreover, we found that unique nontraditional factors, such as ambulatory status and discharge destination, are significant predictors of NOAC use.
Adoption of new therapies may take well over a decadeeven when clinical practice guidelines with robust evidence are available. 15, 16 For example, in the first several years after publication of pivotal trials demonstrating warfarin's efficacy in stroke prevention, such as Atrial Fibrillation, Aspirin, Anticoagulation Study, 1989 (AFASAK) and Stroke Prevention in Atrial Fibrillation Study, 1991 (SPAF), there were only modest increases in warfarin use among patients with AF from 13% in 1989 to ≈25% in 1991. Although use of anticoagulation for stroke prevention in AF has slowly increased over time, the current anticoagulation rate ≈60% suggests that there remain opportunities for improvement. 12 Despite potential practical advantages of NOACs over warfarin, such as reduced need for monitoring and lower intracranial hemorrhage rates, our study shows similarly modest early adoption rates for NOAC therapy. Our observed rate of uptake at 16% to 17% falls in the upper range of estimates among studies describing early utilization patterns. A report from the Danish National Register showed 5.2% uptake by fourth quarter 2011, whereas reports from the United States have shown higher early adoption rates-12% in the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF) Registry by August 2011 to as high as 16 .9% in a report from the National Disease and Therapeutic Index survey by December 2011. 13, 14 In part, the modest adoption rate of NOACs in the acute ischemic stroke and TIA population may be because of differences in the patient population encountered in acute ischemic stroke and TIA care compared with the pivotal AF trials evaluating NOACs. Compared with the patients studied in those clinical trials, our study population was older (≈77-79 versus ≈71-73), with a higher proportion of women (≈48.6%-62.5% versus ≈33.1%-46.6%), and with higher mean CHADS 2 , consistent with our high-risk confirmed ischemic stroke/TIA population. [3] [4] [5] 17 Therefore, it is not surprising that the use of NOACs is different given the differences in treating inpatients hospitalized with stroke or TIA compared with the trial populations, which treated predominantly ambulatory patients with AF.
Previous reports from ORBIT-AF, the National Disease and Therapeutic Index, and the Danish National Patient Register also focused on outpatients or a mix of outpatients/ inpatients with AF. In contrast, our patient population was exclusively inpatient and had higher CHADS 2 and CHA 2 DS 2 -VASc stroke risk scores. 13, 14 Nevertheless, our data agree with these previous studies by suggesting cautious uptake of NOAC therapy by physicians, mirroring the risk-treatment mismatch previously observed for warfarin therapy in AF, with higher age, bleeding risk, and stroke risk being associated with less warfarin use. [18] [19] [20] NOACs confer equal or better protection from stroke than warfarin with a lower intracerebral hemorrhage risk and no increase in major bleeding rates, [3] [4] [5] and our current analysis showed patients discharged on NOACs had lower CHADS 2 stroke risk scores. Moreover, NOAC use had less association with bleeding risk factors, such as older age, concurrent antiplatelet therapy, and impaired ambulation. [21] [22] [23] Although bleeding risk is an important clinical consideration, reports of real-world dabigatran use compared with warfarin in United States-and Denmark-based registries showed no increases in bleeding. In fact, these reports found lower intracerebral hemorrhage rates. 24, 25 Although information on real-world rivaroxaban use is limited, these reports suggest that bleeding events described in case studies and series may overstate the actual bleeding risk compared with clinical trials and population-based registries, highlighting the need for further investigation into the real-world efficacy and bleeding risk for NOAC-treated patients.
Similar to ORBIT-AF, we also identified racial and financial differences in anticoagulant choice. We found that white patients had a higher odds of NOAC prescription than other races, echoing racial disparities previously described for AF anticoagulation. 14, 19, 26 Closely related to this, it would seem that financial access to NOACs was a major determinant of their use because lack of health insurance, Medicaid, and Medicare were associated with a lower odds of NOAC therapy compared with warfarin. High out-of-pocket costs are a deterrent to new prescription drug adherence, 24 and even with health insurance, affordability may have been a concern because of substantial copays or cumbersome preapprovals. 27 Given the favorable risk-benefit profile of NOACs compared with warfarin, further work is needed to close the gap conferred by financial and social barriers.
One question of interest is whether patients who are being treated with NOACs are newly initiated or switched from warfarin to NOAC therapy. GWTG-Stroke does not collect information on the specific admission anticoagulant, but it is reasonable to assume that patients on anticoagulation before hospitalization were likely on warfarin therapy during this study period. Using this assumption, as many as 38% of patients could have been warfarin to NOAC switchers, whereas 62% were possibly new starts. Although discharge NOAC use increased during this study period, the use of warfarin (and especially non-NOAC/nonwarfarin agents, such as low-molecular weight heparins) decreased markedly. Nonetheless, the total percentage of eligible patients discharged to home without an anticoagulant did not change appreciably (from 6.6%-5.9%). Therefore, rather than growing the pie of patients anticoagulated for AF, NOACs may be preferentially prescribed in place of non-NOAC/nonwarfarin anticoagulants, and to a lesser degree, in place of warfarin. Finally, 1.4% of patients discharged on NOACs had prosthetic heart valves and 30.9% had coronary artery disease despite the possibility of adverse events while on dabigatran, which was the predominant NOAC during this study period. 3, 28, 29 Further education on the risks and benefits of NOAC therapy may be needed to increase familiarity with these drugs and prevent risk-treatment mismatches or adverse events.
Our study had several limitations. First, GWTG-Stroke is a voluntary quality improvement program and may not represent prescribing patterns at nonparticipating hospitals. For example, GWTG hospitals compared with American Hospital Association Hospitals were more likely to be teaching hospitals (45.2 versus 23.7%; P<0.001), less likely to be rural (12.5 versus 35.1%; P<0.001), and were larger (median bed size, 255 versus 88; P<0.001). Second, prescription patterns among those being discharged after ischemic stroke or TIA could differ from those of ambulatory patients with AF treated in the outpatient setting. Moreover, previous exposure to anticoagulants may have been an important confounder in the decision to either discharge on anticoagulation or on the choice of anticoagulant. Third, we only evaluated those patients discharged on oral anticoagulant therapy, and available data did not allow us to assess patterns of prescribing for new starts at hospital follow-up. Fourth, we were unable to assess adherence to discharge anticoagulant therapy after hospital discharge. Fifth, it must be noted that rivaroxaban was only available for the latter 15 months of the study period, and with current availability of apixaban and the ongoing dissemination of information regarding NOACs, current usage patterns may differ. Sixth, we were unable to perform a formal bleeding risk assessment because we lacked data for key components of wellvalidated bleeding risk models, such as previous bleeding episodes, and we did not include a formal assessment of stroke severity in logistic regression modeling because the National Institute of Health stroke scale had a high missing rate (29%). 21, 23, 30 Finally, residual measured and unmeasured confounders may still exist, particularly because we were unable to determine all clinical and social circumstances that could have influenced treatment selection from the registry, such as patient choice, prescribing physician specialty, or payer mix and decisions.
In conclusion, among AF patients hospitalized with ischemic stroke or TIA, use of NOACs have been modestly integrated into clinical practice, although they tend to be used in patients with lower stroke risk and better functional status. Use of NOACs varied widely by hospital and overall anticoagulation rates at hospital discharge among eligible patients with stroke and TIA did not increase appreciably. Future investigations should consider linking to claims data to further explore adherence rates, longitudinal outcomes, and safety of NOACs in clinical practice. 16 .6% from first quarter of 2011 to second quarter of 2012 (P for nonzero correlation<0.001). Warfarin use and non-NOAC/nonwarfarin anticoagulant use declined during the same time period (78.8%-72.4% for warfarin and 14.6%-4.7% for non-NOAC/nonwarfarin agents). The proportion of eligible patients who were not anticoagulated at hospital discharge did not change appreciably (from 6.3%-5.9%), suggesting that NOAC use did not increase the proportion of patients anticoagulated at hospital discharge but were used in place of other anticoagulation strategies. Note: the total number lines were not extended to Q4 2010 and Q3 2012 because these quarters were truncated by our prespecified study period, thereby limiting the number of patients included for those quarters. Q indicates quarter.
Figure 2.
Hospital-level novel oral anticoagulant (NOAC) use at discharge. There was considerable site-level variation in NOAC use at hospital discharge among patients hospitalized with ischemic stroke/transient ischemic attack and atrial fibrillation. Among 1347 sites with >5 NOAC prescriptions during the study period, the median rate of discharge NOAC versus warfarin therapy was 9.6% (interquartile range, 4.0-16.7), with a range from 0% to 62.5%.
